NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB

• Main Author: E. L. Nasonov
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2014-06-01
• Series: Научно-практическая ревматология
• Subjects: rheumatoid arthritis; tofacitinib; jak inhibitors.
• Online Access: https://rsp.mediar-press.net/rsp/article/view/1928

One of the breakthroughs in pharmacology of the XXI century is the development of a new class of drugs, which are low molecular weight (<1 kDa), chemically synthesized substances (small molecules) intended for oral administration. Their point of application is tyrosine kinases, the enzymes involved in regulation of intracellular signaling that deter- mines the biological activity of cytokines. Tofacitinib (TOFA, Tofacitinib, Yakvinus; Pfizer), the first oral reversible inhibitor of JAK approved for treatment of rheumatoid arthritis (RA), is of special interest. The clinical efficacy and low toxicity of TOFA have been proved in a series of phase III randomized placebo-controlled studies, combined under the acronym ORAL, which has included more than 5000 patients with RA. Further research is needed, aimed at assessing the efficacy and safety of TOFA during prolonged use in real-life clinical practice (including through national registers) in patients with various forms of RA and comorbid diseases. It is reasonable to conduct «strategic» research of TOFA, designed in accordance with the concept of goal-directed treatment.